Skip to content
Dyne Therapeutics Logo

Dyne Therapeutics: May Letter to the DMD Community

May 21, 2024

Defeat Duchenne Canada is pleased to share an update to the Duchenne Muscular Dystrophy Community from Dyne Therapeutics.

Dyne Therapeutics is working to advance their proprietary FORCETM platform to overcome the limitations of muscle tissue delivery, with the stated mission to deliver life-transforming therapies for people living with serious muscle diseases.

Recognizing a shared sense of urgency with the DMD community to accelerate potential therapies, we are pleased to now share new clinical data from the ongoing DYNE-251 DELIVER trial. This is in advance of our anticipated plan to provide data in the second half of 2024. Our clinical data continues to demonstrate the promise of the FORCETM platform.

The most recent data shares efficacy and safety data from patients with DMD amenable to exon 51 skipping enrolled in the 10 mg/kg (approximate PMO dose) cohort of the randomized, placebo-controlled MAD portion of the DYNE-251 DELIVER trial.

Dyne Therapeutics

Defeat Duchenne Canada will continue to keep the Canadian DMD community up to date and share new industry information as it becomes available.

Learn more about their efforts and the key findings from DELIVER in this official letter below.

Related Articles